RESUMEN
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread and have grave health and socioeconomic consequences worldwide. Researchers have raced to understand the pathophysiological mechanisms underpinning the disease caused by SARS-CoV-2 so that effective therapeutic targets can be discovered. This review summarises the key pharmacotherapies that are being investigated for treatment of COVID-19, including antiviral, immunomodulator and anticoagulation strategies.
Asunto(s)
Anticoagulantes/uso terapéutico , Antivirales/uso terapéutico , Tratamiento Farmacológico de COVID-19 , Glucocorticoides/uso terapéutico , Factores Inmunológicos/uso terapéutico , Inhibidores de Agregación Plaquetaria/uso terapéutico , Adenosina Monofosfato/análogos & derivados , Adenosina Monofosfato/uso terapéutico , Alanina/análogos & derivados , Alanina/uso terapéutico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Azetidinas/uso terapéutico , COVID-19/terapia , Colchicina/uso terapéutico , Dexametasona/uso terapéutico , Humanos , Inmunización Pasiva , Ivermectina/uso terapéutico , Inhibidores de las Cinasas Janus/uso terapéutico , Purinas/uso terapéutico , Pirazoles/uso terapéutico , SARS-CoV-2 , Sulfonamidas/uso terapéutico , Sueroterapia para COVID-19RESUMEN
The UK government recently decided to extend the interval between the first dose of the Pfizer BioNTech and AstraZeneca COVID-19 vaccines from 3 weeks to 12 weeks to maximise the number of people receiving the initial dose, despite the trials only providing vaccine efficacy data based on a schedule of 21 days between doses. This editorial discusses whether there is evidence to support this policy change.